A plain-English guide to what research peptides are, how they work in the body, and what the published science actually shows — with citations you can look up yourself. This page is not a sales page. It's here to help you understand the science before you form an opinion.
What is a peptide?
A peptide is a short chain of amino acids — the same building blocks that make up proteins, just far fewer of them. Where a protein might contain hundreds or thousands of amino acids folded into a complex shape, a peptide is typically 2 to 50 linked together. That smaller size is the whole point: peptides are short enough to act as precise signalling molecules.
Your body already makes thousands of them. Insulin is a peptide. So is the hunger hormone ghrelin, and the gut hormone GLP-1 that several modern metabolic-research compounds are modelled on. When researchers talk about “research peptides,” they usually mean lab-synthesised versions of these naturally occurring signals — or close analogues designed to last longer or bind more tightly than the natural molecule.
The one-sentence version: peptides are small protein fragments the body uses as chemical messages, and research peptides are synthetic versions scientists use to study those messages.
How do peptides actually work?
Most peptides work by fitting into a receptor — a docking site on the surface of a cell — the way a key fits a lock. When the peptide binds, it tells that cell to do something: release a hormone, ramp up repair, change how it handles sugar or fat. Because each peptide is shaped to fit specific receptors, they tend to be selective: they nudge one pathway rather than flooding the whole system.
A few terms you'll see everywhere, in plain language:
Agonist — a molecule that switches a receptor on. A “GLP-1 agonist” activates the GLP-1 receptor.
Half-life — how long it takes for half of a compound's concentration to clear from a system. It's a core pharmacokinetic property (long half-life → slow clearance; short → rapid clearance).
Receptor selectivity — how narrowly a peptide targets one receptor versus several. Newer metabolic compounds deliberately hit two or three receptors at once.
How peptides are studied (and why “research grade” matters)
Evidence comes in tiers, and it's worth knowing which tier any claim sits in:
In-vitro — studied in cells or test tubes. Useful for mechanism, but a long way from proving anything in a living body.
Preclinical (animal) — tested in animal models. Promising signals here often don't translate to humans.
Clinical (human) — tested in people across phased trials. Phase 3 trials with thousands of participants are the gold standard.
This distinction is the most important thing on this page. Some peptides (the GLP-1 class below) have large, published, peer-reviewed human trials. Others (several repair and growth-hormone peptides) have only preclinical evidence — interesting, but unproven in humans. Honest sources tell you which is which. We've tried to.
Separately, “research grade” refers to purity and identity verification — confirming a vial actually contains what the label says, at the stated purity, via methods like HPLC (purity) and mass spectrometry (identity). A legitimate supplier publishes the measured result for each lot.
GLP-1 & incretin peptides (the metabolic-research class)
This is the most heavily studied peptide category in modern medicine, with multiple large human trials. These compounds mimic incretins — gut hormones released after eating that influence insulin secretion and glucose regulation.
Semaglutide
How it works: a single-target GLP-1 receptor agonist. By binding and activating GLP-1 receptors, it modulates insulin secretion and glucose-dependent signalling pathways studied in receptor pharmacology.
What the research shows: the landmark STEP 1 trial is among the most extensively documented studies of a GLP-1 receptor agonist. See the citation below to review the published findings.
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021;384(11):989–1002 (PMID 33567185). · Status: Approved & widely studied in humans
How it works: a dual agonist — it activates both GLP-1 and GIP receptors. Hitting two incretin pathways at once appears to produce stronger metabolic effects than targeting GLP-1 alone.
What the research shows: the SURMOUNT-1 trial characterised its dual-agonist pharmacology in a large human study, and a later head-to-head trial (SURMOUNT-5) compared it with semaglutide. See the citation below.
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022;387(3):205–216 (PMID 35658024). · Status: Approved & studied in humans
How it works: a triple agonist — it activates GLP-1, GIP, and glucagon receptors (nicknamed “triple-G”). Adding the glucagon receptor is studied for its influence on energy metabolism in receptor-pharmacology research.
What the research shows: its published Phase 2 trial characterised the triple-agonist pharmacology. The Phase 3 TRIUMPH and TRANSCEND programs have since reported: TRANSCEND-T2D-1 was published in The Lancet in June 2026, the first retatrutide Phase 3 dataset to clear peer review, while the remaining Phase 3 figures are sponsor-reported topline results that have not yet been peer-reviewed. Retatrutide is not approved anywhere, and Eli Lilly has said it plans to file for FDA approval in 2027.
Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023;389(6):514–526 (PMID 37366315). · TRANSCEND-T2D-1, The Lancet, 2026, doi:10.1016/S0140-6736(26)00967-0 (PMID 42250575). · Status: Investigational — Phase 3 reported, not approved
This category is popular in research discussion but sits on a very different evidence tier from the GLP-1 class: the human data is limited or absent, and most findings come from animal studies. Read accordingly.
BPC-157 (Body Protection Compound)
How it works (proposed): a synthetic peptide derived from a protein found in gastric juice. In animal models it appears to promote blood-vessel formation (angiogenesis) and influence growth-factor pathways involved in tissue healing.
What the research shows: a large body of preclinical work — primarily rodent studies led by researchers such as Sikirić and colleagues — reports accelerated healing of tendon, ligament, muscle, and gut tissue. Importantly, there are no completed large-scale human efficacy trials. The human evidence is essentially anecdotal at this stage.
Seiwerth S, Ručman R, Turković B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design, 2018;24(18):1972–1989 (PMID 29998800). · Status: Preclinical only — unproven in humans
How it works (proposed): a synthetic fragment related to thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair via regulation of actin, a structural protein inside cells.
What the research shows: thymosin beta-4 has been explored in early human studies for wound and cardiac repair, but TB-500 specifically is supported mainly by preclinical data. Robust human efficacy data is lacking.
Philp D, Kleinman HK. Animal studies with thymosin β4, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010;1194:81–86 (PMID 20536453). · Status: Mostly preclinical / early-stage
These don't supply growth hormone — they prompt the pituitary gland to release more of the body's own. They're studied in growth-hormone-axis and tissue-repair research, with a mix of early human and preclinical evidence.
CJC-1295 (no DAC) & Ipamorelin
How it works: a complementary pairing. CJC-1295 without DAC — also called modified GRF (1-29) — is a short-acting GHRH analogue that increases the amount of GH released; Ipamorelin is a selective GH secretagogue that triggers a clean pulse of release without strongly affecting other hormones. Used together, they're studied for additive effects.
What the research shows: the early human pharmacology of the GHRH analogue class is characterised in the Teichman 2006 study cited below, which studied the DAC form and reported an estimated half-life of 5.8–8.1 days. The no-DAC form we stock behaves very differently — it clears in roughly 30 minutes, which is precisely why it is studied for pulsatile rather than sustained GH release. Ipamorelin's selectivity is well characterised in preclinical work. Long-term human outcome trials are limited for both.
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799–805 (PMID 16352683) — note: this study used the DAC form. · Status: Early human + preclinical
How it works: a selective ghrelin-receptor (GHS-R1a) agonist. It triggers growth-hormone release with minimal effect on cortisol or prolactin, which is what distinguishes it from the older, less selective growth-hormone-releasing peptides.
What the research shows: its selectivity is well characterised in preclinical pharmacology, which is why it is favoured as a research tool for isolating GHS-R1a signalling. Human studies are small and long-term human outcome data is essentially absent.
Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139(5):552–561 (PMID 9849822). · Status: Preclinical / limited human
How it works: a stabilised GHRH(1–44) analogue that binds the GHRH receptor on the pituitary, prompting release of the body's own growth hormone. The stabilisation slows enzymatic breakdown relative to native GHRH.
What the research shows: this is the best-evidenced compound in this section. Tesamorelin is an approved drug (as Egrifta) for HIV-associated lipodystrophy, and its effect on visceral adipose tissue has been characterised in randomised human trials. That makes it one of the few GHRH analogues with genuine Phase 3 human data behind it.
Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007;357(23):2359–2370 (PMID 18057338). · Status: Approved & studied in humans
Evidence quality varies more sharply in this category than in any other we stock. Several compounds here have decades of published human work concentrated in a single national literature with little independent Western replication. That is a material limitation, not a footnote.
Semax
How it works: a synthetic heptapeptide. Its sequence is the ACTH(4–7) fragment extended with a Pro-Gly-Pro tail, which is what makes it resistant to rapid enzymatic breakdown; the literature also refers to it as an analogue of the ACTH(4–10) fragment, and both descriptions refer to the same molecule. It is studied for effects on BDNF and NGF expression, dopaminergic and serotonergic signalling, and oxidative-stress pathways.
What the research shows: Semax has been a registered pharmaceutical in Russia for decades and has been studied there in stroke and cognitive-impairment settings. Its pharmacodynamic (effect-duration) data is richer than its Western plasma-kinetics data, and independent replication outside that literature is limited. Treat the mechanistic work as better established than the clinical claims.
We are not citing a single anchor trial for Semax, because the Western peer-reviewed literature on it is thin and we would rather say so than dress up a weak evidence base. Search Semax on PubMed and judge it yourself. · Status: Registered (Russia); limited Western trials
This group is studied less for growth or repair and more for how cells produce energy, handle glucose, and age. The evidence is mostly preclinical, but the mechanisms are unusually well-characterised.
MOTS-c
How it works: a mitochondrial-derived peptide — a 16-amino-acid peptide encoded within the mitochondrial genome's 12S rRNA (MT-RNR1), not the cell nucleus. It acts on the folate–AICAR pathway to activate AMPK, a master regulator of cellular energy, which is why it's often called an "exercise-mimetic" in metabolic research.
What the research shows: Lee and colleagues (2015) reported that MOTS-c promoted metabolic homeostasis and reduced diet-induced obesity and insulin resistance in mice. Reynolds and colleagues (2021) reported that MOTS-c is induced by exercise in human muscle and circulation, and that treating mice enhanced physical performance in young, middle-aged and old animals. Human data remains early.
Lee C et al. Cell Metabolism, 2015;21(3):443–454 (PMID 25738459) · Reynolds JC et al. Nature Communications, 2021;12:470 (doi 10.1038/s41467-020-20790-0). · Status: Mostly preclinical / emerging
How it works: a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine bound to copper(II)), first isolated from human plasma by Loren Pickart in 1973. Circulating levels are reported to decline with age. In research models it modulates wound-repair gene expression, stimulates collagen and glycosaminoglycan synthesis, and shows antioxidant activity.
What the research shows: fibroblast and wound-model studies report collagen stimulation and matrix remodelling; reviews by Pickart and Margolina summarise broad gene-expression effects relevant to skin and tissue repair. The bulk of evidence is preclinical or topical.
Pickart L (isolation from human plasma, 1973) · Pickart L, Margolina A. Int. J. Molecular Sciences, 2018;19(7):1987 (PMID 29986520). · Status: Preclinical / topical
Being honest about limits is part of good science:
Animal results don't guarantee human results. Many compounds that heal rat tendons do nothing measurable in people. Preclinical promise is a hypothesis, not a conclusion.
Trial averages aren't individual outcomes. A trial reporting a given mean effect describes a population average; individuals varied widely above and below it.
Long-term safety data is often thin, especially for newer or preclinical-only compounds.
Purity is not optional. Without a lot-matched analytical result, you don't actually know what's in a vial — which makes any other claim meaningless.
Quick glossary
Amino acids
The building blocks that link together to form peptides and proteins.
Agonist
A molecule that activates (switches on) a receptor.
Receptor
A docking site on a cell that a peptide binds to in order to send its signal.
Half-life
Time for half of a compound's concentration to clear from a system; a core pharmacokinetic property.
Incretin
A gut hormone (like GLP-1 or GIP) released after eating that affects insulin secretion and glucose metabolism.
Lyophilised
Freeze-dried into a stable powder for storage and laboratory handling.
Excipient
An inactive ingredient present in a vial alongside the compound — a bulking agent or buffer salt, for example — that supports the physical form and stability of the finished material.
COA
Certificate of Analysis — lab documentation of a lot's purity and identity.
HPLC
High-Performance Liquid Chromatography; the standard test for purity.
In-vitro / preclinical / clinical
The three rising tiers of evidence: test tube → animal → human.
References & further reading
These are starting points — search any of them on PubMed (pubmed.ncbi.nlm.nih.gov) to read the abstracts and follow the primary literature yourself.
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PMID 33567185. PubMed →
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PMID 35658024. PubMed →
Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). N Engl J Med. 2023;389(6):514–526. PMID 37366315. PubMed →
TRANSCEND-T2D-1 (retatrutide Phase 3, type 2 diabetes). The Lancet. 2026. doi:10.1016/S0140-6736(26)00967-0. PMID 42250575. PubMed →
Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des. 2018;24(18):1972–1989. PMID 29998800.
PubMed →
Philp D, Kleinman HK. Animal studies with thymosin β4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81–86. PMID 20536453.
PubMed →
Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 (DAC form). J Clin Endocrinol Metab. 2006;91(3):799–805. PMID 16352683. PubMed →
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PMID 9849822. PubMed →
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. PMID 18057338. PubMed →
Semax — no single anchor trial; the Western literature is thin. PubMed →
Important: This page is educational and summarises published scientific research about peptide compounds. It is not medical advice, and nothing here is a treatment recommendation. Clinical-trial results describe study populations, not outcomes you should expect. Products sold by ThePeptide are intended strictly for in-vitro laboratory research and are not for human consumption. Always consult qualified professionals and the primary literature before drawing conclusions.
Research library
The science behind every compound we stock.
A research summary for each compound in the catalogue, with a link straight to its full guide and to the product itself. Every claim cited to primary literature. Written for researchers, not marketers.
Compound research
Every compound, with its full research guide
13 compounds. Each summary answers the question directly, then links to the complete guide.
🧬
Metabolic
Retatrutide
What is retatrutide and how does triple receptor agonism work?
Retatrutide (LY3437943) is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors simultaneously. The glucagon arm is what separates it from dual agonists such as tirzepatide: it adds thermogenic activity, increasing energy expenditure in ways GLP-1 or GIP agonism alone do not. Phase 2 results were published in the New England Journal of Medicine in 2023 (Jastreboff et al., PMID 37366315) and the Phase 3 TRIUMPH programme is ongoing.
What is semaglutide and what does GLP-1 receptor agonism do?
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and one of the most extensively studied metabolic peptides in the literature. It is an acylated analogue of native GLP-1, modified at position 8 to resist DPP-4 degradation, which extends its half-life substantially over the endogenous hormone. The STEP clinical programme forms the core of the published evidence base.
What is tirzepatide and how does dual GIP/GLP-1 agonism differ from GLP-1 alone?
Tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors from a single 39-amino-acid backbone. Adding GIP receptor activity to GLP-1 agonism produced larger effects in the SURMOUNT and SURPASS trial programmes than GLP-1 agonism on its own. It is the compound that established multi-receptor targeting as a distinct research direction.
What is BPC-157 and what does the tissue repair research actually show?
BPC-157 is a synthetic pentadecapeptide of 15 amino acids derived from a protective protein in human gastric juice. The most replicated preclinical finding is accelerated tendon healing, attributed to FAK-paxillin pathway activation and VEGF-driven angiogenesis. The evidence base is almost entirely rodent; there are no completed human efficacy trials, and the guide states that plainly.
What does the BPC-157 and TB-500 combination research show?
The Wolverine Blend pairs BPC-157 with TB-500, a synthetic fragment of Thymosin Beta-4. The two are studied together because their proposed mechanisms are complementary rather than overlapping: BPC-157 acts largely through angiogenesis and FAK-paxillin signalling, while TB-500 works through actin sequestration, freeing actin monomers for cell migration and tissue remodelling.
What is TB-500 and how does actin sequestration work?
TB-500 is a synthetic analogue of Thymosin Beta-4, a 43-amino-acid protein present in virtually all nucleated mammalian cells and concentrated in platelets and wound fluid. Its central mechanism is actin sequestration: it binds actin monomers and makes them available for cell migration. Cardiac research in rodent infarct models has shown reduced infarct size and cardiac progenitor activation.
What is GHK-Cu and why is the copper complex significant?
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, CAS 49557-75-7. The tripeptide has high affinity for copper(II), and the complex — not the bare peptide — is the form studied for collagen synthesis and wound remodelling. Plasma GHK concentration declines markedly with age, which is the observation that originally drove research interest.
What is MOTS-c and what makes a mitochondrial-derived peptide different?
MOTS-c is a 16-amino-acid peptide encoded within the 12S rRNA region of mitochondrial DNA rather than the nuclear genome, which is what makes it a mitochondrial-derived peptide. Research centres on AMPK pathway activation and the folate-methionine cycle, positioning it as a signal from mitochondria to the nucleus rather than a conventional metabolic hormone.
What is ipamorelin and why is receptor selectivity the point?
Ipamorelin is a pentapeptide ghrelin receptor agonist and growth hormone secretagogue. Its defining property in the literature is selectivity: unlike earlier secretagogues such as GHRP-6 and GHRP-2, it stimulates GH release with minimal effect on cortisol, prolactin or ACTH. That clean profile is the reason it remains a reference compound in secretagogue research.
Why are CJC-1295 and ipamorelin studied as a pair?
The two act on different receptors along the same axis. CJC-1295 is a GHRH analogue that increases the amplitude of growth hormone pulses; ipamorelin is a ghrelin receptor agonist that increases their frequency. Because the mechanisms are complementary rather than duplicative, the combination is studied as a single system in the secretagogue literature.
What is tesamorelin and how does it differ from other GHRH analogues?
Tesamorelin is a stabilised synthetic analogue of human growth hormone-releasing hormone, GHRH(1-44). A trans-3-hexenoyl group on the N-terminus resists DPP-4 cleavage, extending its half-life over native GHRH. It is one of the few compounds in this class to have completed large randomised human trials, which makes its evidence base unusually well characterised.
Semax is a synthetic heptapeptide analogue of ACTH(4-10) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Research shows it upregulates brain-derived neurotrophic factor and its receptor TrkB in hippocampal tissue. Most of the published work comes from Russian research groups studying rodent models of cerebral ischemia, where it reduced infarct volume and improved neurological scores.
What is bacteriostatic water and why does the benzyl alcohol matter?
Bacteriostatic water is sterile water containing 0.9% benzyl alcohol, supplied as a general laboratory consumable. The benzyl alcohol is a preservative that inhibits microbial growth, which is what distinguishes it from plain sterile water for injection. It is stocked here as a laboratory supply; this site publishes no preparation, dilution or handling guidance for any compound.
Purity, identity and net peptide content, reported by an independent laboratory and published per lot. Free tracked shipping Canada-wide, no minimum, dispatched within 48 hours.